Ensoma Closes Series B Extension, Bringing Total Round to $135 Million

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/10/2026

1. HUM
2. SPCX
3. ALHC
4. T
5. PEP
6. TMUS
7. SPY
8. CVS
9. UNH
10. AXP

Go back to Ensoma Closes Series B Extension, Bringing Total Round to $135 Million

Gilead Sciences (GILD) cell therapy unit can grow to multi-billion dollar business by end of 2023 - BMO Capital

May 16, 2023 9:22 AM EDT

BMO Capital's Evan David Seigerman upgraded Gilead Sciences (NASDAQ: GILD) to Outperform from Market Perform, raising the price target to $100 per share from $90 in a note Tuesday.

The analyst pointed to three key factors for the upgrade, which were the company's best-in-class cell... More